4.7 Review

Retinal Inflammation, Cell Death and Inherited Retinal Dystrophies

Journal

Publisher

MDPI
DOI: 10.3390/ijms22042096

Keywords

retinal dystrophies; cell death; inflammation; TNFα

Funding

  1. European Regional Development Fund
  2. Spanish Ministry of Economy, Industry, and Competitiveness (MINECO) Carlos III Health Institute (ISCIII) [PI18/00252]
  3. ONCE

Ask authors/readers for more resources

Inherited retinal dystrophies (IRDs) are a group of retinal disorders that lead to progressive vision loss due to retinal cell death, predominantly photoreceptor cells. The treatment of IRDs is complicated by genetic and clinical heterogeneity, but reducing retinal inflammation has emerged as an effective approach to slowing disease progression.
Inherited retinal dystrophies (IRDs) are a group of retinal disorders that cause progressive and severe loss of vision because of retinal cell death, mainly photoreceptor cells. IRDs include retinitis pigmentosa (RP), the most common IRD. IRDs present a genetic and clinical heterogeneity that makes it difficult to achieve proper treatment. The progression of IRDs is influenced, among other factors, by the activation of the immune cells (microglia, macrophages, etc.) and the release of inflammatory molecules such as chemokines and cytokines. Upregulation of tumor necrosis factor alpha (TNF alpha), a pro-inflammatory cytokine, is found in IRDs. This cytokine may influence photoreceptor cell death. Different cell death mechanisms are proposed, including apoptosis, necroptosis, pyroptosis, autophagy, excessive activation of calpains, or parthanatos for photoreceptor cell death. Some of these cell death mechanisms are linked to TNF alpha upregulation and inflammation. Therapeutic approaches that reduce retinal inflammation have emerged as useful therapies for slowing down the progression of IRDs. We focused this review on the relationship between retinal inflammation and the different cell death mechanisms involved in RP. We also reviewed the main anti-inflammatory therapies for the treatment of IRDs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available